Doctors share common rheumatoid arthritis symptoms, from wrist pain and swollen joints to fatigue, dry eyes, and skin nodules ...

This measure of how well controlled your psoriatic arthritis is can be used to guide treatment decisions.

A new study has found that biologic class and treatment sequencing influences psoriatic arthritis risk in patients with ...

BMS has secured approval from the European Commission for Sotyktu (deucravacitinib) to treat active psoriatic arthritis (PsA).

European Commission approves Bristol Myers Squibb’s Sotyktu for the treatment of active psoriatic arthritis in adults: Princeton, New Jersey Monday, May 11, 2026, 15:00 Hrs [IST ...

In the pivotal Phase 3 POETYK PsA clinical trials, Sotyktu demonstrated superiority compared with placebo at Week 16 across multiple endpoints, including skin and joint symptoms, with improvements in ...

A 27-year-old woman from Colchester living with psoriatic arthritis has become the face of a national campaign to raise ...

Alert EU Backs New Oral Option in Psoriatic Arthritis The European Medicines Agency has endorsed expanded use of Sotyktu for psoriatic arthritis, recommending approval after clinical trials showed ...

Ixekizumab plus tirzepatide (IXE+TZP) shows significant benefits over ixekizumab (IXE) alone in adults with active psoriatic arthritis (PsA) who are overweight or have obesity, according to a study ...

Psoriatic arthritis (PsA) is a long-lasting condition that affects the joints in people who have a skin condition called psoriasis. When you have PsA, your immune system mistakenly attacks your own ...

(RTTNews) - Bristol Myers Squibb (BMY) announced that the U.S. Food and Drug Administration has approved Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis (PsA).

People who took both Zepbound and an anti-inflammatory drug saw a greater improvement of their psoriatic arthritis symptoms. ©2026 GIZMODO USA LLC. All rights ...